This opinion piece discusses the state of stem cell research in the U.S. following the decision by U.S. President Barack Obama to lift government restrictions on the use of these materials. The beginning of a clinical trial by the Geron Corp., which will test an embryonic stem-cell based therapy for spinal cord injuries is framed in terms of the length of time between the beginning of clinical trials and the approval of therapies. Continued political controversies over stem cells are noted.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados